Compare Abbott Laboratories (ABT) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Atlassian Corporation PLC — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Atlassian Corporation PLC trades at $85.4 (market cap $22.43B). The key difference: Abbott Laboratories is far larger — about 7.4× Atlassian Corporation PLC's market cap, and Abbott Laboratories pays a 2.63% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| ABT | TEAM | |
|---|---|---|
Market Cap | $166.94B | $22.43B |
Sector | Health | Technology |
52-Week High | $136.62 | $220.89 |
52-Week Low | $82.57 | $57.15 |
Enterprise Value | $193.69B | $22.54B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Atlassian (TEAM) trades at $88.39, up 5.43% with bullish technical signals despite negative profitability metrics. The stock shows strong revenue growth from $2.8B in 2022 to $5.2B in 2025, though net losses persist. Recent earnings beats and cloud revenue momentum of 29% in Q3 FY26 support optimism. Analyst consensus is strongly bullish with 30 buy ratings and a $120.29 price target, representing 36% upside potential.
The outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent losses, high valuation multiples, and competitive pressures. With improving margins and strong institutional support, TEAM offers growth exposure but requires tolerance for current unprofitability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
